Table 1.

Summary of the characteristics of different tested compounds.

	Siplizumab	Alemtuzumab	rATG	References
Target antigen	CD2	CD52	Thymocyte antigens
Type of protein	mAb	mAb	pAb
ADCC/ADCP	+	+1	+1	Figure 1
CDC	0	+1	+1	Figure 1
T cell depletion	+	+	+	Figure 3
T cell activation	−	+	+	Figures 6 and 7
T cell proliferation	−	0	+	Figure 2
Tn enrichment	+	+/−	0	Figure 4
Treg enrichment	+	+/−	+	Figure 5
NK cell activation	+	+	+	Figure 8

ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cell phagocytosis; CDC, complement-dependent cytolysis; mAb, monoclonal antibody; pAb, polyclonal antibody; +, increases given effect; −, inhibits given effect/read-out; 0, no change/does not induce given effect; +/−, inconclusive assay results.

¹See text for references.